Cover Image
市場調查報告書

蛋白質治療藥的全球市場 (2016∼2020年)

Global Protein Therapeutics Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 345849
出版日期 內容資訊 英文 130 Pages
訂單完成後即時交付
價格
Back to Top
蛋白質治療藥的全球市場 (2016∼2020年) Global Protein Therapeutics Market 2016-2020
出版日期: 2015年11月25日 內容資訊: 英文 130 Pages
簡介

全球蛋白質治療藥市場預計2015∼2020年,以8%的年複合成長率(CAGR) 成長。尤其是佔市場55%的單株抗體的需求增加,促進市場整體的成長。為了抑制高額的治療費,全球各國推動醫療費償付制度的整備,也成為市場成長的原因之一。在各地區中,北美有55%的市場佔有率。另一方面,市場非常細分化,多數的企業,在市場上也展開激烈競爭,不過,今後由於企業合併、收購 (M&A),一般認為小規模的企業將進行淘汰。

本報告提供全球蛋白質治療藥市場相關分析、產品概要和市場結構、市場規模趨勢 (今後5年的預測值)、各產品種類及各治療領域、各地區的詳細趨勢、推動&阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查評估。

第1章 摘要整理

  • 分析結果的概要

第2章 分析範圍

  • 分析概要
  • 大供應商的主要產品

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

  • 市場趨勢的概要

第5章 市場環境

  • 市場概要
  • 市場規模與其預測
  • 波特的五力分析

第6章 各產品種類的市場區隔

第7章 全球單株抗體藥市場

  • 簡介
  • 市場概要
  • 推動市場要素
  • 市場課題
  • 市場趨勢
  • 供應商資訊

第8章 全球胰島素市場

第9章 全球促血紅細胞生長素市場

第10章 全球人體生長荷爾蒙市場

第11章 各治療領域的市場區隔

  • 代謝、內分泌障礙
  • 造血
  • 肥胖症
  • 癌症
  • 自體免疫疾病
  • 感染疾病
  • 蛋白質疫苗

第12章 蛋白質的各功能的市場區隔

  • 酵素活性、調整活動
  • 特殊標的活動
  • 疫苗
  • 蛋白質診斷

第13章 地區區分

  • 全球蛋白質治療藥市場:各地區的詳細趨勢 (今後6年份)
  • 南北美洲市場
  • 歐洲、中東、非洲地區 (EMEA) 市場
  • 亞太地區市場

第14章 推動市場要素

  • 單株抗體的需求增加
  • 良好的醫療費償付政策
  • 慢性疾病的患病人數增加
  • 有潛力的藥劑開發平台
  • 活躍的產品開發

第15章 推動因素的影響力

第16章 市場課題

  • 暢銷醫藥品的專利到期
  • 嚴格的法規
  • 治療費高
  • 激烈的市場競爭
  • 副作用的風險

第17章 推動因素、課題的影響力

第18章 市場趨勢

  • 患者支援計劃
  • 策略性的產業聯盟
  • 標靶治療的誕生
  • 興趣轉向未開發市場
  • 在一般社會的知名度上升

第19章 供應商環境

  • 競爭方案
  • 市場佔有率分析
  • 其他卓越供應商

第20章 主要供應商分析

  • AbbVie
  • Amgen
  • F.Hoffmann-La Roche
  • Johnson & Johnson
  • Merck Serono
  • Novo Nordisk

第21章 附錄

  • 簡稱集

第22章 關於Technavio

圖表一覽

目錄
Product Code: IRTNTR8020

Market outlook of the protein therapeutics market

Technavios market research analyst predicts the global protein therapeutics market to grow steadily at a CAGR of 8% during the forecast period. Increased demand for and use of monoclonal antibodies is expected to drive the growth of the protein therapeutics market as it accounts for more than half of the protein therapeutics market. The monoclonal antibodies can be prepared specific to any cell surface or extracellular target. These antibodies are being used in radioimmunotherapy and antibody-directed enzyme prodrug therapy. Monoclonal antibodies are also used in the formulation of various biopharmaceutical drugs for the treatment of different diseases such as cancer, rheumatoid arthritis, multiple sclerosis, and UC.

The availability of favorable reimbursement policies in this market is expected to boost the market growth during the forecast period. Protein therapeutics are expensive and cannot be afforded by all, but reimbursement of the diagnostic kits and biologic drugs are expected to fuel the market during the forecast period. Plans like the public reimbursement programs reduce the financial burden of treatments. The reimbursement status of drugs varies from region to region, with factors such as lack of cost-effectiveness impeding the coverage.

Product segmentation and analysis of the protein therapeutics market

  • Monoclonal antibodies
  • Erythropoietin
  • Insulin
  • Human growth hormone
  • Interferons
  • Blood clotting factor
  • G-CSF
  • Follicle stimulating hormone

The monoclonal antibodies segment dominated the market during 2015, with a market share of 55%. An increase in the prevalence of cancer and autoimmune diseases, increase in research activities, and increased technological advancement in the development of next-generation antibodies are the main factors fueling the growth of this segment.

Geographical segmentation and analysis of the protein therapeutics market

  • Americas
  • APAC
  • EMEA

The Americas accounted for 48% of the market share during 2015 and is expected to grow at a CAGR of 7% during the forecast period. The promising public health approaches by the government, growing incidence, and an increase in regulatory support for the development of protein therapeutics are the primary drivers for the market growth in this region.

Competitive landscape and key vendors

The global protein therapeutics market is highly fragmented due to the presence of numerous small and large vendors. The vendors in the market compete on the basis of price, quality, and innovation. Competition among the vendors has led an increased number of M&A, wherein smaller entities are being acquired by, or are being merged with, major players.

The leading vendors in the market are -

  • AbbVie
  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novo Nordisk

Other prominent vendors in the market include Anhui Anke Biotechnology, AstraZeneca, Baxter International, Biocon, Biodel, Biogenomics, BioPartners, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Chugai Pharmaceutical, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Dynavax Technologies, Eli Lilly, Ferring Pharmaceuticals, Generex Biotechnology, GeneScience Pharmaceuticals, Hualan Biological Engineering, Intas Pharmaceuticals, Ipsen, JCR Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, LG Life Sciences, Macrogenics, MannKind, Oramed Pharmaceuticals, Osiris Therapeutics, Pfizer, Sandoz International, Sanofi, Teva Pharmaceutical Industries, Thermalin Diabetes, Tolerion, Wockhardt, and XOMA.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020
  • What are the key factors driving the global protein therapeutics market
  • What are the key market trends impacting the growth of the protein therapeutics market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the vendors in the global protein therapeutics market
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA
  • What are the key outcomes of the five forces analysis of the protein therapeutics market

Technavio also offers customization on reports based on specific client requirement.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by product type

PART 07: Global monoclonal antibody drugs market

  • Introduction
  • Market overview
  • Market drivers
  • Market challenges
  • Market trends
  • Vendors of global monoclonal antibody drugs market

PART 08: Global insulin market

  • Introduction
  • Market overview
  • Market drivers
  • Market challenges
  • Market trends
  • Insulin market in Europe
  • Vendors of global insulin market

PART 09: Global erythropoietin market

  • Introduction
  • Market overview
  • Market drivers
  • Market challenges
  • Market trends
  • Erythropoietin market in Japan
  • Vendors of global erythropoietin market

PART 10: Global human growth hormone market

  • Introduction
  • Market overview
  • Market drivers
  • Market challenges
  • Market trends
  • Vendors of global human growth hormone market

PART 11: Market segmentation by therapy area

  • Metabolic and endocrine disorders
  • Hematopoiesis
  • Fertility
  • Cancer
  • Autoimmune diseases
  • Infectious diseases
  • Protein vaccine

PART 12: Market segmentation by protein function

  • Enzymatic and regulatory activity
  • Special targeting activity
  • Vaccines
  • Protein diagnostics

PART 13: Geographical segmentation

  • Global protein therapeutics market by geographical segmentation 2015-2020
  • Protein therapeutics market in Americas
  • Protein therapeutics market in EMEA
  • Protein therapeutics market in APAC

PART 14: Market drivers

  • Increased demand for monoclonal antibodies
  • Availability of favorable reimbursement policies
  • Increasing prevalence of chronic diseases
  • Promising drug pipeline
  • Frequent innovations

PART 15: Impact of drivers

PART 16: Market challenges

  • Patent expiration of top-selling drugs
  • Stringent regulations
  • High cost of therapy
  • Fierce market competition
  • Risk of side effects

PART 17: Impact of drivers and challenges

PART 18: Market trends

  • Patient assistance programs
  • Strategic alliances
  • Emergence of targeted therapies
  • Shifting focus toward untapped markets
  • Increase in public awareness

PART 19: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • Other prominent vendors

PART 20: Key vendor analysis

  • AbbVie
  • Amgen
  • F.Hoffmann-La Roche
  • Johnson & Johnson
  • Merck Serono
  • Novo Nordisk

PART 21: Appendix

  • List of abbreviations

PART 22: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global protein therapeutics market 2015-2020 ($ billions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Segmentation of global protein therapeutics market by product type
  • Exhibit 05: Global protein therapeutic market segment by product type based on revenue, 2015
  • Exhibit 06: Top-selling monoclonal antibodies based on revenue, 2014 ($ billions)
  • Exhibit 07: Global monoclonal antibody market 2015-2020 ($ billions)
  • Exhibit 08: Global human insulin market 2015-2020 ($ billions)
  • Exhibit 09: Insulin market in Europe 2015-2020 ($ billions)
  • Exhibit 10: Globally approved erythropoietin biosimilars
  • Exhibit 11: Global erythropoietin market 2015-2020 ($ billions)
  • Exhibit 12: Erythropoietin market in Japan 2015-2020 ($ millions)
  • Exhibit 13: Global human growth hormone market 2015-2020 ($ billions)
  • Exhibit 14: Segmentation of global protein therapeutics market by therapy area
  • Exhibit 15: Segmentation of global protein therapeutics market by protein function
  • Exhibit 16: Global protein therapeutics market by geography, 2015
  • Exhibit 17: Global protein therapeutics market revenue by geography 2015-2020 ($ billions)
  • Exhibit 18: Protein therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 19: Protein therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 20: Protein therapeutics market in APAC 2015-2020 ($ billions)
  • Exhibit 21: Monoclonal antibody approvals by FDA and EMA from 2010-2014
  • Exhibit 22: Impact of drivers
  • Exhibit 23: Impact of drivers and challenges
  • Exhibit 24: Roche: YoY growth and revenue generated from net product sales of Actemra 2011-2014 ($ millions)
  • Exhibit 25: Roche: YoY growth and revenue generated from net product sales of Avastin 2011-2014 ($ millions)
  • Exhibit 26: Roche: YoY growth and revenue generated from net product sales of Herceptin 2011-2014 ($ millions)
  • Exhibit 27: Roche: Revenue generated from net product sales of Kadcyla 2013-2014 ($ millions)
  • Exhibit 28: Roche: YoY growth and revenue generated from net product sales of Lucentis 2011-2014 ($ millions)
  • Exhibit 29: Roche: YoY growth and revenue generated from net product sales of MabThera/Rituxan 2011-2014 ($ millions)
  • Exhibit 30: Roche: YoY growth and revenue generated from net product sales of Mircera 2011-2014 ($ millions)
  • Exhibit 31: Roche: YoY growth and revenue generated from net product sales of NeoRecorm/Epogin 2011-2014 ($ millions)
  • Exhibit 32: Roche: YoY growth and revenue generated from net product sales of Pegasys 2011-2014 ($ millions)
  • Exhibit 33: Roche: YoY growth and revenue generated from net product sales of Perjeta 2012-2014 ($ millions)
  • Exhibit 34: Roche: YoY growth and revenue generated from net product sales of Pulmozyme 2011-2014 ($ millions)
  • Exhibit 35: Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2014 ($ millions)
  • Exhibit 36: Novo Nordisk: YoY growth and revenue generated from net product sales of Levemir 2011-2014 ($ millions)
  • Exhibit 37: Novo Nordisk: YoY growth and revenue generated from net product sales of NovoRapid/NovoLog 2011-2014 ($ millions)
  • Exhibit 38: Novo Nordisk: YoY growth and revenue generated from net product sales of NovoMix 2011-2014 ($ millions)
  • Exhibit 39: Novo Nordisk: YoY growth and revenue generated from net product sales of human insulins 2011-2014 ($ millions)
  • Exhibit 40: Novo Nordisk: YoY growth and revenue generated from net product sales of NovoSeven 2011-2014 ($ millions)
  • Exhibit 41: Novo Nordisk: YoY growth and revenue generated from net product sales of Norditropin 2011-2014 ($ millions)
  • Exhibit 42: Amgen: YoY growth and revenue generated from net product sales of Aranesp 2011-2014 ($ millions)
  • Exhibit 43: Amgen: YoY growth and revenue generated from net product sales of Enbrel 2011-2014 ($ millions)
  • Exhibit 44: Amgen: YoY growth and revenue generated from net product sales of EPOGEN 2011-2014 ($ millions)
  • Exhibit 45: Amgen: YoY growth and revenue generated from net product sales of Neulasta 2011-2014 ($ millions)
  • Exhibit 46: Amgen: YoY growth and revenue generated from net product sales of NEUPOGEN 2011-2014 ($ millions)
  • Exhibit 47: Amgen: YoY growth and revenue generated from net product sales of Vectibix 2011-2014 (excluding Japan) ($ millions)
  • Exhibit 48: Amgen: YoY growth and revenue generated from net product sales of XGEVA 2011-2014 ($ millions)
  • Exhibit 49: Amgen: YoY growth and revenue generated from net product sales of Prolia 2011-2014 ($ millions)
  • Exhibit 50: AbbVie: YoY growth and revenue generated from net product sales of HUMIRA 2011-2014 ($ millions)
  • Exhibit 51: AbbVie: YoY growth and revenue generated from net product sales of Synagis 2011-2014 ($ millions)
  • Exhibit 52: AbbVie: YoY growth and revenue generated from net product sales of Lupron 2011-2014 ($ millions)
  • Exhibit 53: Johnson & Johnson: YoY growth and revenue generated from net product sales of Procrit 2011-2014 ($ millions)
  • Exhibit 54: Johnson & Johnson: YoY growth and revenue generated from net product sales of Remicade 2011-2014 ($ millions)
  • Exhibit 55: Johnson & Johnson: YoY growth and revenue generated from net product sales of Simponi 2011-2014 ($ millions)
  • Exhibit 56: Johnson & Johnson: YoY growth and revenue generated from net product sales of Stelara 2011-2014 ($ millions)
  • Exhibit 57: Merck: YoY growth and revenue generated from net product sales of Erbitux except US and Canada 2011-2014 ($ millions)
  • Exhibit 58: Merck: YoY growth and revenue generated from net product sales of Pegintron 2011-2014 ($ millions)
  • Exhibit 59: Merck: YoY growth and revenue generated from net product sales of Remicade 2011-2014 ($ millions)
  • Exhibit 60: Merck: YoY growth and revenue generated from net product sales of Simponi 2011-2014 ($ millions)
  • Exhibit 61: AbbVie: Product segmentation by revenue 2014
  • Exhibit 62: AbbVie: Product segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 63: AbbVie: Geographical segmentation by revenue 2014
  • Exhibit 64: Amgen: Business segmentation by revenue 2014
  • Exhibit 65: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 66: Amgen: Geographical segmentation by revenue 2014
  • Exhibit 67: Roche: Business segmentation by revenue 2014
  • Exhibit 68: Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 69: Roche: Geographical segmentation by revenue 2014
  • Exhibit 70: Johnson & Johnson: Business segmentation
  • Exhibit 71: Merck Serono: Product segmentation 2014
  • Exhibit 72: Merck Serono: Geographical segmentation by revenue 2014
  • Exhibit 73: Novo Nordisk: Business segmentation by revenue 2014
  • Exhibit 74: Novo Nordisk: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 75: Novo Nordisk: Geographical segmentation by revenue 2014
  • Exhibit 76: Novo Nordisk: R&D expenditure 2014
Back to Top